Study TypeCognitive Impairment & Alzheimer's Disease
Study PurposeThe purpose of this research study is to test the safety and tolerability of the investigational drug MK-8931 in the treatment of subjects with Mild Cognitive Impairment (aMCI) due to Alzheimer's Disease (AD).
About the StudyMK-8931 is a new drug that is being studied by Merck to see if it has any effect in treating Alzheimer's disease.
- 1 Screening visit
- 11 Clinic visits over a two year period
- ~8 telephone calls
- Height, weight, vitals, physical and neurological exam
- PET scan
- Electrocardiogram (ECG)
- Urinalysis and blood draws
- Questionnaires and interviews
- Eye exam
- MK-8931 12mg once a day
- MK-8931 40mg once a day
- Placebo once a day
Number of visits:
Eligible participants will be assigned by chance to one of the following treatment groups:
- Age: 50-85
- You meet the criteria for a diagnosis of probable Alzheimer’s Disease as determined by a PET scan at the screening visit
- You have a clear history of cognitive and functional decline over at least one year that is either documented in medical records or documented by report from an informant who knows you well
Study Duration26 months
CompensationEarn up to $975 for participation.
Study ContactIf you are interested in volunteering for this trial, call the Institute for Dementia Research and Prevention at 225-763-2973 or email firstname.lastname@example.org.
For additional information on clinical trials by investigator or sponsor, please visit clinicaltrials.gov